328 related articles for article (PubMed ID: 19355932)
1. Alternative Abeta immunotherapy approaches for Alzheimer's disease.
Town T
CNS Neurol Disord Drug Targets; 2009 Apr; 8(2):114-27. PubMed ID: 19355932
[TBL] [Abstract][Full Text] [Related]
2. Amyloid-beta immunotherapy for Alzheimer's disease.
Fu HJ; Liu B; Frost JL; Lemere CA
CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):197-206. PubMed ID: 20205640
[TBL] [Abstract][Full Text] [Related]
3. AD vaccines: conclusions and future directions.
Wisniewski T
CNS Neurol Disord Drug Targets; 2009 Apr; 8(2):160-6. PubMed ID: 19355935
[No Abstract] [Full Text] [Related]
4. Rationale for peptide and DNA based epitope vaccines for Alzheimer's disease immunotherapy.
Ghochikyan A
CNS Neurol Disord Drug Targets; 2009 Apr; 8(2):128-43. PubMed ID: 19355933
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models.
Wisniewski T; Boutajangout A
Brain Struct Funct; 2010 Mar; 214(2-3):201-18. PubMed ID: 20012091
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy for Alzheimer's disease: rational basis in ongoing clinical trials.
Menéndez-González M; Pérez-Piñera P; Martínez-Rivera M; Muñiz AL; Vega JA
Curr Pharm Des; 2011; 17(5):508-20. PubMed ID: 21375481
[TBL] [Abstract][Full Text] [Related]
7. Vaccination strategies for Alzheimer's disease: A new hope?
Woodhouse A; Dickson TC; Vickers JC
Drugs Aging; 2007; 24(2):107-19. PubMed ID: 17313199
[TBL] [Abstract][Full Text] [Related]
8. Antibody responses, amyloid-beta peptide remnants and clinical effects of AN-1792 immunization in patients with AD in an interrupted trial.
Kokjohn TA; Roher AE
CNS Neurol Disord Drug Targets; 2009 Apr; 8(2):88-97. PubMed ID: 19355930
[TBL] [Abstract][Full Text] [Related]
9. Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention.
Cribbs DH
CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):207-16. PubMed ID: 20205639
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy in a natural model of Abeta pathogenesis: the aging beagle.
Vasilevko V; Head E
CNS Neurol Disord Drug Targets; 2009 Apr; 8(2):98-113. PubMed ID: 19355931
[TBL] [Abstract][Full Text] [Related]
11. Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice.
Petrushina I; Ghochikyan A; Mktrichyan M; Mamikonyan G; Movsesyan N; Davtyan H; Patel A; Head E; Cribbs DH; Agadjanyan MG
J Neurosci; 2007 Nov; 27(46):12721-31. PubMed ID: 18003852
[TBL] [Abstract][Full Text] [Related]
12. Critical issues for successful immunotherapy in Alzheimer's disease: development of biomarkers and methods for early detection and intervention.
Tarawneh R; Holtzman DM
CNS Neurol Disord Drug Targets; 2009 Apr; 8(2):144-59. PubMed ID: 19355934
[TBL] [Abstract][Full Text] [Related]
13. 'Clinical trials in Alzheimer's disease': immunotherapy approaches.
Delrieu J; Ousset PJ; Caillaud C; Vellas B
J Neurochem; 2012 Jan; 120 Suppl 1():186-193. PubMed ID: 21883222
[TBL] [Abstract][Full Text] [Related]
14. Developing novel immunogens for a safe and effective Alzheimer's disease vaccine.
Lemere CA
Prog Brain Res; 2009; 175():83-93. PubMed ID: 19660650
[TBL] [Abstract][Full Text] [Related]
15. Amyloid-beta immunisation for Alzheimer's disease.
Wisniewski T; Konietzko U
Lancet Neurol; 2008 Sep; 7(9):805-11. PubMed ID: 18667360
[TBL] [Abstract][Full Text] [Related]
16. Strikingly reduced amyloid burden and improved behavioral performance in Alzheimer's disease mice immunized with recombinant chimeric vaccines by hexavalent foldable Aβ₁₋₁₅ fused to toxin-derived carrier proteins.
Yu YZ; Wang WB; Chen A; Chang Q; Liu S; Zhao M; Wang S; Qiu WY; Pang XB; Xu Q; Sun ZW
J Alzheimers Dis; 2014; 41(1):243-60. PubMed ID: 24625800
[TBL] [Abstract][Full Text] [Related]
17. Immunization with the SDPM1 peptide lowers amyloid plaque burden and improves cognitive function in the APPswePSEN1(A246E) transgenic mouse model of Alzheimer's disease.
Wang CM; Devries S; Camboni M; Glass M; Martin PT
Neurobiol Dis; 2010 Sep; 39(3):409-22. PubMed ID: 20493257
[TBL] [Abstract][Full Text] [Related]
18. Refining an Alzheimer's vaccine to avoid an inflammatory response.
Brown ME; DaSilva KA; McLaurin J
Expert Opin Biol Ther; 2005 Jun; 5(6):809-16. PubMed ID: 15952911
[TBL] [Abstract][Full Text] [Related]
19. [Development of antibodies for immunotherapy of Alzheimer's disease].
Matsumoto SE; Jin H; Takeda K; Hasegawa Y; Motoi Y; Hattori N; Tabira T
Rinsho Shinkeigaku; 2012; 52(11):1168-70. PubMed ID: 23196552
[TBL] [Abstract][Full Text] [Related]
20. Active and passive Abeta-immunotherapy: preclinical and clinical studies and future directions: part II.
Cribbs DH; Agadjanyan MG
CNS Neurol Disord Drug Targets; 2009 Apr; 8(2):82-7. PubMed ID: 19355929
[No Abstract] [Full Text] [Related]
[Next] [New Search]
